Opko GHD candidate fails Phase III study in adults

Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK) on Friday reported its long-acting human growth hormone (hGH) analog hGH-CTP missed the primary endpoint in a Phase III trial to treat adults with growth hormone deficiency. The study evaluated the effect of weekly hGH-CTP injections vs. placebo on change in trunk fat mass from baseline to 26 weeks.

Opko lost $2.16 (19%) to $9.30 on NASDAQ on the day, shedding about $1.2 billion in market cap. The Tel Aviv Stock Exchange was closed...